Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
